Innovative, long-acting treatments – for patients and society
Camurus is committed to improving the lives of patients with severe and chronic diseases
Learn more
Delivering better treatments
Camurus is committed to improving the lives of patients with severe and chronic diseases
Learn moreupdates
Latest news
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Change in number of shares and votes in Camurus
Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism
Disease areas
Focus on severe and chronic diseases
Developing treatments for diseases within the central nervous system, rare diseases, endocrinology, oncology and supportive care.
Events
Upcoming events
-
12Feb
Full Year Report 2025
The full year report 2025 is published on 12 February 2026.
-
12Feb
Interim Report January-December 2025 – Webcast
Financial analysts, investors and media are invited to attend a webcast and presentation of the results at 2.00 pm CET.
Access the webcast using this link: Webcast
To participate in the presentation and ask questions, please register using the link below. After registering, please use the provided phone number and conference ID to dial in. Register to dial in
-
11Mar
Danske Bank Small & Mid Cap Seminar
Camurus’ President & CEO Fredrik Tiberg is presenting at this conference in Stockholm, 11 March. The presentation can be seen by the conference participants. More information will follow closer to the event.
Latest financial report
Camurus’ Interim Report Third Quarter 2025
6 November 2025
Pipeline
Diversified pipeline with large potential
Camurus’ innovative product candidates are designed to address important unmet medical needs, with the potential to make significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.
sustainability
Sustainable solutions for a healthier world
Ensuring the long-term successful development of our business – for the benefit of patients, healthcare systems, employees and shareholders.
